Institutional Investor Whetstone Capital Reduces Stake in Health Catalyst
HCAT sits 81% above its 52-week low of $0.955 on elevated volume (2.1× avg).
Summary
Institutional investor Whetstone Capital Advisors sold over $4.7 million in Health Catalyst stock, reducing its stake to 4.5% following the company's recent divestiture announcement.
Key Events · Ownership and Investor Activity · HCAT
-
Significant Stock Sales
Whetstone Capital Advisors sold 2,524,251 shares of common stock on June 4-5, 2026, for a total value of approximately $4.72 million.
-
Reduced Ownership Stake
The sales reduced Whetstone Capital Advisors' beneficial ownership to 3,285,690 shares, representing 4.5% of Health Catalyst's common stock.
-
Post-Divestiture Selling
These sales occurred immediately after Health Catalyst announced the divestiture of its Vitalware business unit for $147 million in cash on June 4, 2026.
Analysis · HCAT · Technology
Whetstone Capital Advisors, an institutional investor, significantly reduced its stake in Health Catalyst by selling over $4.7 million worth of common stock. This divestment, occurring immediately after the company announced a $147 million business unit divestiture, suggests a lack of confidence despite recent efforts to improve the balance sheet. The reduction to 4.5% ownership marks a notable decrease in their position.
At the time of this filing, HCAT was trading at $1.72 on NASDAQ in the Technology sector, with a market capitalization of approximately $128.9M. The 52-week trading range was $0.96 to $4.29. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.